Showing 2781-2790 of 3039 results for "".
- CDC Updates Guidance for Public Gatheringshttps://modernod.com/news/cdc-updates-guidance-for-coronavirus-disease-2019/2477385/On Sunday, the Centers for Disease Control and Prevention (CDC) updated its guidance regarding public gatherings during the COVID-19 outbreak. The CDC now recommends that for the next 8 weeks, organizers (whether groups or individuals) cancel or postpone in-person events that consist of 50
- Top Contact Lens Experts Dispel Misinformation Regarding Coronavirushttps://modernod.com/news/top-contact-lens-experts-dispel-misinformation-regarding-coronavirus/2477381/Three of the world’s most published researchers in eye health are responding to misinformation circulating regarding contact lens and spectacles/glasses wear amidst Novel Coronavirus/COVID-19 pandemic. Lyndon Jones, director of the Centre for Ocular Research & Education (CORE) at the U
- WHO Declares COVID-19 Outbreak a Pandemic; Eye Care Meetings Cancelledhttps://modernod.com/news/who-declares-covid-19-outbreak-a-pandemic/2477374/The World Health Organization on Wednesday said the COVID-19 outbreak can now “be characterized as a pandemic.” The declaration by Director-General Tedros Adhanom Ghebreyesus was made after he noted that “in the past 2 weeks the number of cases outside China has increased thirteen-fold and the nu
- Long-Term Visual Acuity Unaffected by Intraocular Lens Implantation After Congenital-Cataract Surgeryhttps://modernod.com/news/long-term-visual-acuity-unaffected-by-intraocular-lens-implantation-after-congenital-cataract-surgery/2477357/Intraocular lens implantation at the time of surgery for congenital cataract during infancy neither improves nor worsens long-term visual acuity, compared with correction with contact lenses, according to findings from the Infant Aphakia Treatment Study (IATS), as
- Nicox’s End-of-Phase 2 Meeting With the FDA Sets Stage for NCX 470 Phase 3 Program in Glaucomahttps://modernod.com/news/nicoxs-end-of-phase-2-meeting-with-the-fda-sets-stage-for-ncx-470-phase-3-program-in-glaucoma/2477350/Nicox announced that it has successfully completed an end-of-phase 2 meeting with the FDA and agreed on the design for the NCX 470 phase 3 program, as well as nonclinical and CMC plans supporting submission of a new drug application (NDA) in the U.S. NCX 470, a novel second generation nitric oxid
- AAO Alert: Coronavirus Update for Ophthalmologistshttps://modernod.com/news/aao-alert-coronavirus-updates-for-ophthalmologists/2477347/The Academy is sharing important ophthalmology-specific information related to the novel coronavirus, referred to as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was previously known by the provisional name 2019-nCoV. The highly contagious virus can cause a severe respirato
- ImprimisRx Announces Supply Agreement with Vision Center Network of America (VCNA)https://modernod.com/news/imprimisrx-announces-supply-agreement-with-vision-center-network-of-america-vcna/2477342/ImprimisRx announced that it has agreed to a product supply agreement with Vision Center Network of America LLC (VCNA). The agreement will make ImprimisRx a VCNA preferred provider for a variety of surgical formulations, including a portfolio of topical and injectable products. Terms of t
- Registration Open for Eyecelerator, a New Conference Aimed at Accelerating Eye Care Advancementshttps://modernod.com/news/registration-open-for-eyecelerator-a-new-conference-accelerating-eye-care-advancements/2477339/Registration is now open for Eyecelerator, a new business conference aimed at furthering ophthalmic innovation. The conference is a joint venture between the American Academy of Ophthalmology (AAO) and the American Society of Cataract and Refractive Surgery (ASCRS). The inaugural Eyecelerator con
- EyePoint Pharmaceuticals Announces Positive Topline 36-Month Follow-up Data for Second Phase 3 Study of Yutiqhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-positive-topline-36-month-follow-up-data-for-second-phase-3-study-of-yutiq/2477336/EyePoint Pharmaceuticals announced positive topline 36-month follow-up data from the second phase 3 trial of Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year micro-insert for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye. “The d
- Zeiss Concludes Acquisition of Saxonia Systems and Creates Carl Zeiss Digital Innovation in Dresden, Germanyhttps://modernod.com/news/zeiss-concludes-acquisition-of-saxonia-systems-and-creates-carl-zeiss-digital-innovation-in-dresden-germany/2477335/Zeiss has concluded its acquisition of Saxonia Systems AG, a specialist for customized software solutions. The fully acquired company will now operate as Carl Zeiss Digital Innovation. The new unit will support the Zeiss segments with their digital projects and play a leading role in terms of inn